Cargando...
Daily patient-reported health status assessment improvements with benralizumab for patients with severe, uncontrolled eosinophilic asthma
BACKGROUND: Patients with severe, uncontrolled asthma experience debilitating symptoms that result in meaningful reductions to health-related quality of life. Benralizumab is an interleukin-5 receptor alpha–directed cytolytic monoclonal antibody that reduces exacerbations and improves asthma symptom...
Gardado en:
| Publicado en: | J Asthma Allergy |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Dove Medical Press
2019
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6350639/ https://ncbi.nlm.nih.gov/pubmed/30774388 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JAA.S190221 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|